Profound Medical forecasts Q3 revenue between $9.8M and $10M

Preliminary unaudited results for Profound Medical Corp. (NASDAQ: PROF; TSX: PRN) indicate third-quarter 2026 revenue will land between $9.8 million and $10.0 million, a range the company stated exceeds the Bloomberg mean analyst consensus of $6.78 million by approximately 45% to 47%. The figures, announced on October 7, 2026, are expected to mark a record for the company's quarterly revenue.

Profound projected year-over-year growth of approximately 85% to 89% compared with $5.3 million in the third quarter of 2025. Sequentially, the company expects revenue to increase by approximately 292% to 300% relative to the $2.5 million reported in the second quarter of 2026. The preliminary results also indicate that the gross margin for the third quarter of 2026 is expected to exceed 70%. Profound attributed the growth to increased commercial activity across its installed base and new customer accounts.

Arun Menawat, CEO and Chairman of Profound Medical, described the expected revenue increase as a historic milestone reflecting strong commercial momentum. He noted that the company remains focused on supporting customer adoption and increasing utilization of its installed base to build a profitable growth company over the long term. Menawat emphasized that the preliminary revenue and gross margin figures represent an important step in the continued expansion of the company's commercial business.

The company clarified that these figures are preliminary and unaudited, meaning actual revenues may differ. Profound also stated that it does not endorse, adopt, or control the third-party analyst estimates used for the consensus comparison. The consensus estimate cited was compiled by Bloomberg as of October 7, 2026, at 9:02 a.m. ET.

Profound Medical intends to report its full audited third-quarter 2026 financial results after market close on Thursday, November 5, 2026. The company will host a conference call at 4:30 p.m. ET on that date to review the financial results and discuss business developments. The call will be broadcast live and archived on the company's website in the Investors section.

Profound Medical is a commercial-stage medical device company that develops interventional MRI (iMRI) procedures. Its flagship platform, TULSA-PRO, enables MRI-guided, incision-free prostate ablation and is cleared by the FDA in the United States for transurethral ultrasound ablation of prostate tissue. The device is also cleared for use in various jurisdictions including Europe, Canada, Saudi Arabia, India, Australia/New Zealand, and the UAE. The company also commercializes Sonalleve, an MRI-guided therapy approved by the FDA as a Humanitarian Device Exemption (HDE) for treating osteoid osteomas in limbs. Sonalleve holds clearances or approvals in Europe, Canada, China, and Saudi Arabia.